Premium
Quantum Genomics (ALQGC)
EU
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Firibastat efficacy non-significant versus placeboThe REFRESH study and the development of firibastat in cardiology have been stoppedCash of 11 million euros allotted to the development of new...
PARIS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal...
PARIS, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal...
PARIS, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medications...
PARIS, June 27, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class directly...
PARIS, May 09, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class directly...
PARIS, May 04, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development of a new drug class directly...
PARIS, April 28, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal...
Quantum Genomics has equipped itself with new financial means to pursue the development of firibastat and explore new therapeutic fields based on the patented technology platform built around...
Launch of capital increase of approximately €15 million for institutional investors with cancellation of the pre-emptive subscription rightA minimum of €12 million subscription commitments...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.0721 | 0.0721 | 0.0721 | 0 | 0 | DE |
| 4 | 0 | 0 | 0.0721 | 0.0721 | 0.0721 | 0 | 0 | DE |
| 12 | -0.0004 | -0.551724137931 | 0.0725 | 0.0878 | 0.072 | 27265 | 0.07551079 | DE |
| 26 | -0.0329 | -31.3333333333 | 0.105 | 0.138 | 0.001 | 791206 | 0.05088421 | DE |
| 52 | -0.0295 | -29.0354330709 | 0.1016 | 0.155 | 0.001 | 431890 | 0.05713526 | DE |
| 156 | -4.1639 | -98.2979225685 | 4.236 | 4.462 | 0.001 | 313831 | 0.43677394 | DE |
| 260 | -3.2979 | -97.8605341246 | 3.37 | 6.185 | 0.001 | 311918 | 1.85583543 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
